Skip to main content
. 2015 Jul 21;21(27):8271–8283. doi: 10.3748/wjg.v21.i27.8271

Table 3.

Melanoma studies n (%)

Author Type of microsphere Type of mets (patients) Response criteria Response Median OS
(publish date and study type) (average dosage) @ 1st assessment
Xing et al[49] SIR-Spheres Melanoma (28) RECIST 1.1 5/28 (21) PR 10.1 mo
(8/2014, RS) (mean 1.86 Gbq) 13 cutaneous @ 0.9-1.4 mo 9/28 (38) SD
15 ocular 10/28 (42) PD
4 lost
Memon et al[42] Therasphere Melanoma (16) WHO, RECIST, and EASL WHO 7.6 mo
(6/2014, RS) (median 1.87 Gbq) 7 ocular @ 0.9 mo 5 (31) CR/PR
3 rectal 8 (50) SD
4 cutaneous 3 (19) PD
2 unknown RECIST
5 (31) CR/PR
8 (50) SD
3 (19) PD
EASL
6 (38) CR/PR
7 (43) SD
3 (19) PD
Gonsalves et al[37] SIR-Spheres Ocular melanoma (32) RECIST 1.0 1 (3) CR 10.0 mo
(2/2011, RS) (median 1.08 Gbq) @ 1 mo 1 (3) PR
18 (56) SD
12 (38) PD
Kennedy et al[40] SIR-Spheres Ocular melanoma (11) RECIST 1 (11) CR Median OS not reached
(7/2009, RS) (median 1.55 Gbq) @ 1.4 mo 6 (66) PR
1 (11) SD
1 (11) PD
2 lost
Reiner et al[46] SIR-Spheres Melanoma (2, data extracted from larger study) RECIST 1.1 1 (50) CR/PR None
(1/2014, PC) (mean 1.5 Gbq) @ 4 mo 1 (50) SD/PD
Lim et al[41] SIR-Spheres Ocular melanoma (1, data extracted from larger study) RECIST 1 (100) PD None
(4/2005, PC) (no dosage info) @ 2 mo

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.